Previously treated cases tested for RR-/MDR-TB in France
France: Previously treated cases tested for RR-/MDR-TB was 4.2% in 2024. ◆ Volatile
Previously treated cases tested for RR-/MDR-TB in France, 2005–2024
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for previously treated cases tested for rr-/mdr-tb in France is 4.2%, measured in 2024. That is the lowest value across all 19 years on record.
The figure is down 46.8% on the previous year and down 95.8% over ten years.
Over the whole period, previously treated cases tested for rr-/mdr-tb in France peaked at 100.0% in 2013 and was at its lowest, 4.2%, in 2024.
That places France 170th out of 180 countries with data for 2024, putting it in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Previously treated cases tested for RR-/MDR-TB in France, year by year
| Year | Value | Change |
|---|---|---|
| 2005 | 30.0% | — |
| 2006 | 32.0% | +6.7% |
| 2007 | 26.0% | -18.8% |
| 2008 | 27.0% | +3.8% |
| 2009 | 30.0% | +11.1% |
| 2010 | 29.0% | -3.3% |
| 2011 | 42.0% | +44.8% |
| 2013 | 100.0% | +138.1% |
| 2014 | 100.0% | +0.0% |
| 2015 | 100.0% | +0.0% |
| 2016 | 100.0% | +0.0% |
| 2017 | 98.0% | -2.0% |
| 2018 | 100.0% | +2.0% |
| 2019 | 13.0% | -87.0% |
| 2020 | 11.0% | -15.4% |
| 2021 | 4.8% | -56.4% |
| 2022 | 11.0% | +129.2% |
| 2023 | 7.9% | -28.2% |
| 2024 | 4.2% | -46.8% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 29.0% | 26.0% | 32.0% | 5 |
| 2010s | 75.8% | 13.0% | 100.0% | 9 |
| 2020s | 7.8% | 4.2% | 11.0% | 5 |
Countries ranked near France
- 167 Solomon Islands 9.1% compare
- 168 Algeria 8.2% compare
- 169 Democratic People’s Republic of Korea 5.1% compare
- 171 Gabon 3.7% compare
- 172 Burundi 3.4% compare
- 173 Kiribati 0.0% compare
- 173 South Sudan 0.0% compare
- 173 Tunisia 0.0% compare
- 173 Dominica 0.0% compare
- 173 Palestine, State of 0.0%
- 173 Maldives 0.0% compare
- 173 Vanuatu 0.0% compare
- 173 Timor-Leste 0.0% compare
More health data for France
- Un projection of annual infant deaths, annual growth rate -1.31 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.0689 % change on previous year (2090)
- Heat deaths vs projected death rates 1,016 (2090)
- Un projection of annual infant deaths 603 (2100)
- Population ages 65 and above, female, annual growth rate 1.86 % change on previous year (2025)
- Population ages 65 and above, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 65 and above, female, per capita 0.1274 units per person (2025)
- Population ages 65 and above, male, annual growth rate 2.26 % change on previous year (2025)
- Population ages 65 and above, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 65 and above, male, per capita 0.098 units per person (2025)
Frequently asked questions
- What is previously treated cases tested for rr-/mdr-tb in France?
- Previously treated cases tested for rr-/mdr-tb in France was 4.2% in 2024, according to World Health Organization, Global Health Observatory.
- What is the highest previously treated cases tested for rr-/mdr-tb recorded in France?
- The highest recorded value was 100.0% in 2013.
- What is the lowest previously treated cases tested for rr-/mdr-tb recorded in France?
- The lowest recorded value was 4.2% in 2024.
- How does France rank for previously treated cases tested for rr-/mdr-tb?
- France ranks 170th out of 180 countries with data for 2024.
- Is previously treated cases tested for rr-/mdr-tb rising or falling in France?
- Over the last ten years it is down 95.8%. The long-run trend across the full record is volatile.
- Where does this France data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Previously treated cases tested for RR-/MDR-TB (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 19 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).